1
|
Sakizli U, Takano T, Yoo SK. GALDAR: A genetically encoded galactose sensor for visualizing sugar metabolism in vivo. PLoS Biol 2024; 22:e3002549. [PMID: 38502638 PMCID: PMC10950222 DOI: 10.1371/journal.pbio.3002549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Accepted: 02/14/2024] [Indexed: 03/21/2024] Open
Abstract
Sugar metabolism plays a pivotal role in sustaining life. Its dynamics within organisms is less understood compared to its intracellular metabolism. Galactose, a hexose stereoisomer of glucose, is a monosaccharide transported via the same transporters with glucose. Galactose feeds into glycolysis and regulates protein glycosylation. Defects in galactose metabolism are lethal for animals. Here, by transgenically implementing the yeast galactose sensing system into Drosophila, we developed a genetically encoded sensor, GALDAR, which detects galactose in vivo. Using this heterologous system, we revealed dynamics of galactose metabolism in various tissues. Notably, we discovered that intestinal stem cells do not uptake detectable levels of galactose or glucose. GALDAR elucidates the role for galactokinase in metabolism of galactose and a transition of galactose metabolism during the larval period. This work provides a new system that enables analyses of in vivo sugar metabolism.
Collapse
Affiliation(s)
- Uğurcan Sakizli
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- Division of Developmental Biology and Regenerative Medicine, Kobe University, Kobe, Japan
| | - Tomomi Takano
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
| | - Sa Kan Yoo
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- Division of Developmental Biology and Regenerative Medicine, Kobe University, Kobe, Japan
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
| |
Collapse
|
2
|
Tanaka H, Namkoong H, Chubachi S, Irie S, Uwamino Y, Lee H, Azekawa S, Otake S, Nakagawara K, Fukushima T, Watase M, Kusumoto T, Masaki K, Kamata H, Ishii M, Okada Y, Takano T, Imoto S, Koike R, Kimura A, Miyano S, Ogawa S, Kanai T, Sato TA, Fukunaga K. Clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA in peripheral blood cells. Int J Infect Dis 2023; 135:41-44. [PMID: 37541421 DOI: 10.1016/j.ijid.2023.07.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Revised: 07/20/2023] [Accepted: 07/26/2023] [Indexed: 08/06/2023] Open
Abstract
OBJECTIVES Although SARS-CoV-2 RNAemia has been reported to strongly impact patients with severe COVID-19, the clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA remain unknown. METHODS We included adult patients who had developed COVID-19 between February and September 2020. Total white blood cells derived from the buffy coat of peripheral whole blood were used to detect SARS-CoV-2 RNA using the Illumina COVIDSeq test. We compared the clinical characteristics between patients with and without detected viral RNA (detected and undetected groups). RESULTS Among the 390 patients included, 17 harbored SARS-CoV-2 RNA in peripheral white blood cells. All 17 patients required oxygen support during the disease course and had higher intensive care unit admission (52.9% vs 28.9%, P = 0.035), mortality (17.7% vs 3.5%, P = 0.004), kidney dysfunction (severe, 23.5% vs 6.4%, P = 0.029), and corticosteroid treatment rates (76.5% vs 46.5%, P = 0.016) than those of patients in the undetected group. CONCLUSION We propose that patients with circulating intracellular SARS-CoV-2 RNA in the peripheral blood exhibited the most severe disease course.
Collapse
Affiliation(s)
- Hiromu Tanaka
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Ho Namkoong
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
| | - Shotaro Chubachi
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | | | - Yoshifumi Uwamino
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
| | - Ho Lee
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shuhei Azekawa
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shiro Otake
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Kensuke Nakagawara
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Takahiro Fukushima
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Mayuko Watase
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Katsunori Masaki
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yukinori Okada
- Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan
| | - Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Seiya Imoto
- Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Ryuji Koike
- Clinical Research Center, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan
| | - Akinori Kimura
- Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - Satoru Miyano
- M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Takanori Kanai
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Taka-Aki Sato
- iLAC Co., Ltd., Tsukuba, Ibaraki, Japan; Research and Development Center for Precision Medicine, University of Tsukuba, Ibaraki, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
3
|
Uematsu T, Takano T, Matsui H, Kobayashi N, Ōmura S, Hanaki H. Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model. J Antibiot (Tokyo) 2023; 76:481-488. [PMID: 37185581 PMCID: PMC10127164 DOI: 10.1038/s41429-023-00623-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 03/22/2023] [Accepted: 04/05/2023] [Indexed: 05/17/2023]
Abstract
COVID-19, caused by SARS-CoV-2 infection, is currently among the most important public health concerns worldwide. Although several effective vaccines have been developed, there is an urgent clinical need for effective pharmaceutical treatments for treatment of COVID-19. Ivermectin, a chemical derivative of avermectin produced by Streptomyces avermitilis, is a macrocyclic lactone with antiparasitic activity. Recent studies have shown that ivermectin inhibits SARS-CoV-2 replication in vitro. In the present study, we investigated the in vivo effects of ivermectin in a hamster model of SARS-CoV-2 infection. The results of the present study demonstrate oral administration of ivermectin prior to SARS-CoV-2 infection in hamsters was associated with decreased weight loss and pulmonary inflammation. In addition, the administration of ivermectin reduced pulmonary viral titers and mRNA expression level of pro-inflammatory cytokines associated with severe COVID-19 disease. The administration of ivermectin rapidly induced the production of virus-specific neutralizing antibodies in the late stage of viral infection. Zinc concentrations leading to immune quiescence were also significantly higher in the lungs of ivermectin-treated hamsters compared to controls. These results indicate that ivermectin may have efficacy in reducing the development and severity of COVID-19 by affecting host immunity in a hamster model of SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Takayuki Uematsu
- Biomedical Laboratory, Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Saitama, Japan.
| | - Tomomi Takano
- Laboratory of Veterinary Infectious Disease, Department of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
| | - Hidehito Matsui
- Infection Control Research Center, Ōmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan
| | - Noritada Kobayashi
- Biomedical Laboratory, Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Saitama, Japan
| | - Satoshi Ōmura
- Drug Discovery Project from Natural Products, Ōmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan
| | - Hideaki Hanaki
- Infection Control Research Center, Ōmura Satoshi Memorial Institute, Kitasato University, Minato-ku, Tokyo, Japan
| |
Collapse
|
4
|
Nozawa K, Terada M, Onishi M, Ozaki Y, Takano T, Fakhouri W, Novick D, Haro JM, Faris LH, Kawaguchi T, Tanizawa Y, Tsurutani J. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan. Breast Cancer 2023:10.1007/s12282-023-01461-6. [PMID: 37217763 DOI: 10.1007/s12282-023-01461-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Accepted: 04/08/2023] [Indexed: 05/24/2023]
Abstract
INTRODUCTION This study described, in routine clinical practice in Japan, the patient characteristics, treatment patterns, and outcomes of female patients with HR + /HER2- metastatic breast cancer (MBC) who started abemaciclib treatment. METHODS Clinical charts were reviewed for patients starting abemaciclib in 12/2018-08/2021 with a minimum of 3 months follow-up data post-abemaciclib initiation regardless of abemaciclib discontinuation. Patient characteristics, treatment patterns, and tumor response were descriptively summarized. Kaplan-Meier curves estimated progression-free survival (PFS). RESULTS 200 patients from 14 institutions were included. At abemaciclib initiation, median age was 59 years, and the Eastern Cooperative Oncology Group performance status score was 0/1/2 for 102/68/5 patients (58.3/38.9/2.9%), respectively. Most had an abemaciclib starting dose of 150 mg (92.5%). The percentage of patients receiving abemaciclib as 1st, 2nd, or 3rd line treatment was 31.5%, 25.8%, and 25.2%, respectively. The most frequent endocrine therapy drugs used with abemaciclib were fulvestrant (59%) and aromatase inhibitors (40%). Evaluation of tumor response was available for 171 patients, 30.4% of whom had complete/partial response. Median PFS was 13.0 months (95% CI 10.1-15.8 months). CONCLUSIONS In a routine clinical practice setting in Japan, patients with HR + , HER2- MBC appear to benefit from abemaciclib treatment in terms of treatment response and median PFS, with the results broadly reflecting the evidence demonstrated in clinical trials.
Collapse
Affiliation(s)
- K Nozawa
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Terada
- Department of Breast Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
| | - M Onishi
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Y Ozaki
- Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Takano
- Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - W Fakhouri
- Eli Lilly and Company, Indianapolis, IN, USA
| | - D Novick
- Eli Lilly and Company, Indianapolis, IN, USA
| | - J M Haro
- Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain
| | - L H Faris
- Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain
| | - T Kawaguchi
- Eli Lilly and Company, Indianapolis, IN, USA
| | - Y Tanizawa
- Eli Lilly and Company, Indianapolis, IN, USA
| | - Junji Tsurutani
- Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
| |
Collapse
|
5
|
Okada M, Takano T, Ikegawa Y, Ciesielski H, Nishida H, Yoo SK. Oncogenic stress-induced Netrin is a humoral signaling molecule that reprograms systemic metabolism in Drosophila. EMBO J 2023:e111383. [PMID: 37140455 DOI: 10.15252/embj.2022111383] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 04/01/2023] [Accepted: 04/20/2023] [Indexed: 05/05/2023] Open
Abstract
Cancer exerts pleiotropic, systemic effects on organisms, leading to health deterioration and eventually to organismal death. How cancer induces systemic effects on remote organs and the organism itself still remains elusive. Here we describe a role for NetrinB (NetB), a protein with a particularly well-characterized role as a tissue-level axon guidance cue, in mediating oncogenic stress-induced organismal, metabolic reprogramming as a systemic humoral factor. In Drosophila, Ras-induced dysplastic cells upregulate and secrete NetB. Inhibition of either NetB from the transformed tissue or its receptor in the fat body suppresses oncogenic stress-induced organismal death. NetB from the dysplastic tissue remotely suppresses carnitine biosynthesis in the fat body, which is critical for acetyl-CoA generation and systemic metabolism. Supplementation of carnitine or acetyl-CoA ameliorates organismal health under oncogenic stress. This is the first identification, to our knowledge, of a role for the Netrin molecule, which has been studied extensively for its role within tissues, in humorally mediating systemic effects of local oncogenic stress on remote organs and organismal metabolism.
Collapse
Affiliation(s)
- Morihiro Okada
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
| | - Tomomi Takano
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
| | - Yuko Ikegawa
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- Graduate School of Biostudies, Kyoto University, Kyoto, Japan
| | - Hanna Ciesielski
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Division of Developmental Biology and Regenerative Medicine, Kobe University, Kobe, Japan
| | - Hiroshi Nishida
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Division of Cell Physiology, Kobe University, Kobe, Japan
| | - Sa Kan Yoo
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- Division of Developmental Biology and Regenerative Medicine, Kobe University, Kobe, Japan
| |
Collapse
|
6
|
Nakagawara K, Kamata H, Chubachi S, Namkoong H, Tanaka H, Lee H, Otake S, Fukushima T, Kusumoto T, Morita A, Azekawa S, Watase M, Asakura T, Masaki K, Ishii M, Endo A, Koike R, Ishikura H, Takata T, Matsushita Y, Harada N, Kokutou H, Yoshiyama T, Kataoka K, Mutoh Y, Miyawaki M, Ueda S, Ono H, Ono T, Shoko T, Muranaka H, Kawamura K, Mori N, Mochimaru T, Fukui M, Chihara Y, Nagasaki Y, Okamoto M, Amishima M, Odani T, Tani M, Nishi K, Shirai Y, Edahiro R, Ando A, Hashimoto N, Ogura S, Kitagawa Y, Kita T, Kagaya T, Kimura Y, Miyazawa N, Tsuchida T, Fujitani S, Murakami K, Sano H, Sato Y, Tanino Y, Otsuki R, Mashimo S, Kuramochi M, Hosoda Y, Hasegawa Y, Ueda T, Takaku Y, Ishiguro T, Fujiwara A, Kuwahara N, Kitamura H, Hagiwara E, Nakamori Y, Saito F, Kono Y, Abe S, Ishii T, Ohba T, Kusaka Y, Watanabe H, Masuda M, Watanabe H, Kimizuka Y, Kawana A, Kasamatsu Y, Hashimoto S, Okada Y, Takano T, Katayama K, Ai M, Kumanogoh A, Sato T, Tokunaga K, Imoto S, Kitagawa Y, Kimura A, Miyano S, Hasegawa N, Ogawa S, Kanai T, Fukunaga K. Impact of respiratory bacterial infections on mortality in Japanese patients with COVID-19: a retrospective cohort study. BMC Pulm Med 2023; 23:146. [PMID: 37101265 PMCID: PMC10131342 DOI: 10.1186/s12890-023-02418-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 04/05/2023] [Indexed: 04/28/2023] Open
Abstract
BACKGROUND Although cases of respiratory bacterial infections associated with coronavirus disease 2019 (COVID-19) have often been reported, their impact on the clinical course remains unclear. Herein, we evaluated and analyzed the complication rates of bacterial infections, causative organisms, patient backgrounds, and clinical outcome in Japanese patients with COVID-19. METHODS We performed a retrospective cohort study that included inpatients with COVID-19 from multiple centers participating in the Japan COVID-19 Taskforce (April 2020 to May 2021) and obtained demographic, epidemiological, and microbiological results and the clinical course and analyzed the cases of COVID-19 complicated by respiratory bacterial infections. RESULTS Of the 1,863 patients with COVID-19 included in the analysis, 140 (7.5%) had respiratory bacterial infections. Community-acquired co-infection at COVID-19 diagnosis was uncommon (55/1,863, 3.0%) and was mainly caused by Staphylococcus aureus, Klebsiella pneumoniae and Streptococcus pneumoniae. Hospital-acquired bacterial secondary infections, mostly caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia, were diagnosed in 86 patients (4.6%). Severity-associated comorbidities were frequently observed in hospital-acquired secondary infection cases, including hypertension, diabetes, and chronic kidney disease. The study results suggest that the neutrophil-lymphocyte ratio (> 5.28) may be useful in diagnosing complications of respiratory bacterial infections. COVID-19 patients with community-acquired or hospital-acquired secondary infections had significantly increased mortality. CONCLUSIONS Respiratory bacterial co-infections and secondary infections are uncommon in patients with COVID-19 but may worsen outcomes. Assessment of bacterial complications is important in hospitalized patients with COVID-19, and the study findings are meaningful for the appropriate use of antimicrobial agents and management strategies.
Collapse
Affiliation(s)
- Kensuke Nakagawara
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Hirofumi Kamata
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
| | - Shotaro Chubachi
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Ho Namkoong
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
| | - Hiromu Tanaka
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Ho Lee
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Shiro Otake
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Takahiro Fukushima
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Tatsuya Kusumoto
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Atsuho Morita
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Shuhei Azekawa
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Mayuko Watase
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
- Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan
- Department of Respiratory Medicine, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan
| | - Katsunori Masaki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Akifumi Endo
- Clinical Research Center, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan
| | - Ryuji Koike
- Clinical Research Center, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan
| | - Hiroyasu Ishikura
- Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan
| | - Tohru Takata
- Department of Infection Control, Fukuoka University, Fukuoka, Japan
| | - Yasushi Matsushita
- Department of Internal Medicine and Rheumatology, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Norihiro Harada
- Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | | | | | - Kensuke Kataoka
- Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan
| | - Yoshikazu Mutoh
- Department of Infectious Diseases, Tosei General Hospital, Seto, Japan
| | - Masayoshi Miyawaki
- Department of Internal Medicine, JCHO (Japan Community Health Care Organization, Saitama Medical Center, Saitama, Japan
| | - Soichiro Ueda
- Department of Internal Medicine, JCHO (Japan Community Health Care Organization, Saitama Medical Center, Saitama, Japan
| | - Hiroshi Ono
- Division of Infectious Diseases and Respiratory Medicine, Kumamoto Medical Center, Kumamoto, Japan
| | - Takuya Ono
- Emergency and Critical Care Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan
| | - Tomohisa Shoko
- Emergency and Critical Care Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan
| | - Hiroyuki Muranaka
- Division of Respiratory Medicine, Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc, Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - Kodai Kawamura
- Division of Respiratory Medicine, Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc, Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - Nobuaki Mori
- Department of General Internal Medicine and Infectious Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | - Takao Mochimaru
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| | | | | | - Yoji Nagasaki
- Department of Respirology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Masaki Okamoto
- Department of Respirology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Masaru Amishima
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan
| | - Toshio Odani
- Department of Rheumatology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan
| | - Mayuko Tani
- Ishikawa Prefectural Central Hospital, Kanazawa, Japan
| | - Koichi Nishi
- Ishikawa Prefectural Central Hospital, Kanazawa, Japan
| | - Yuya Shirai
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Ryuya Edahiro
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Akira Ando
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Naozumi Hashimoto
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Shinji Ogura
- Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, Japan
| | - Yuichiro Kitagawa
- Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, Japan
| | - Toshiyuki Kita
- National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan
| | - Takashi Kagaya
- National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan
| | - Yasuhiro Kimura
- Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan
| | - Naoki Miyazawa
- Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan
| | - Tomoya Tsuchida
- Division of General Internal Medicine, Department of Internal Medicine, St. Marianna University School of Medicine Kawasaki, Kawasaki, Japan
| | - Shigeki Fujitani
- Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Koji Murakami
- Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Hirohito Sano
- Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Yuki Sato
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan
| | - Yoshinori Tanino
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan
| | - Ryo Otsuki
- Department of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Japan
| | - Shuko Mashimo
- Department of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Japan
| | - Mizuki Kuramochi
- Department of Gastroenterology, National Hospital Organization Saitama National Hospital, Wako, Saitama, Japan
| | - Yasuo Hosoda
- Department of Gastroenterology, National Hospital Organization Saitama National Hospital, Wako, Saitama, Japan
| | - Yoshinori Hasegawa
- Department of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
| | - Tetsuya Ueda
- Department of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
| | - Yotaro Takaku
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan
| | - Takashi Ishiguro
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan
| | - Akiko Fujiwara
- Department of Medicine, Division of Allergology and Respiratory Medicine, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - Naota Kuwahara
- Department of Medicine, Division of Allergology and Respiratory Medicine, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - Hideya Kitamura
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Eri Hagiwara
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Yasushi Nakamori
- Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Osaka, Japan
| | - Fukuki Saito
- Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Osaka, Japan
| | - Yuta Kono
- Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan
| | - Shinji Abe
- Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan
| | - Tomoo Ishii
- Tokyo Medical University Ibaraki Medical Center, Inashiki, Japan
| | - Takehiko Ohba
- Department of Respiratory Medicine, Ome Municipal General Hospital, Ome, Tokyo, Japan
| | - Yu Kusaka
- Department of Respiratory Medicine, Ome Municipal General Hospital, Ome, Tokyo, Japan
| | - Hiroko Watanabe
- Division of Respiratory Medicine, Tsukuba Kinen General Hospital, Ibaraki, Japan
| | - Makoto Masuda
- Department of Respiratory Medicine, Fujisawa City Hospital, Fujisawa, Japan
| | - Hiroki Watanabe
- Department of Respiratory Medicine, Fujisawa City Hospital, Fujisawa, Japan
| | - Yoshifumi Kimizuka
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan
| | - Yu Kasamatsu
- Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Satoru Hashimoto
- Department of Anesthesiology and Intensive Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Yukinori Okada
- Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan
- Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo, 113-0033, Japan
- Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, 230-0045, Japan
| | - Tomomi Takano
- School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Kazuhiko Katayama
- Laboratory of Viral Infection I, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
| | - Masumi Ai
- Department of Insured Medical Care Management, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan
| | - Atsushi Kumanogoh
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Toshiro Sato
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Katsushi Tokunaga
- Genome Medical Science Project (Toyama), National Center for Global Health and Medicine, Tokyo, Japan
| | - Seiya Imoto
- Division of Health Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
| | - Yuko Kitagawa
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Akinori Kimura
- Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - Satoru Miyano
- M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
| | - Naoki Hasegawa
- Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Takanori Kanai
- Division of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| |
Collapse
|
7
|
Iesato A, Ueno T, Takahashi Y, Kataoka A, Matsunaga Y, Saeki S, Ozaki Y, Inoue Y, Maeda T, Uehiro N, Kobayashi T, Sakai T, Takano T, Kogawa T, Kitano S, Ono M, Osako T, Ohno S. P145 Postpartum breast cancer diagnosed within 10 years of last childbirth is a prognostic factor for distant metastasis – analysis of lymphovascular invasion relating factors. Breast 2023. [DOI: 10.1016/s0960-9776(23)00262-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
8
|
Yamamoto J, Edison L, Rowe-Haas D, Takano T, Gilor C, Crews C, Tuanyok A, Arukha A, Shiomitsu S, Walden H, Hohdatsu T, Tompkins S, Morris J, Sahay B, Kariyawasam S. Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. Viruses 2023; 15:v15040914. [PMID: 37112894 PMCID: PMC10146663 DOI: 10.3390/v15040914] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Revised: 03/23/2023] [Accepted: 03/30/2023] [Indexed: 04/05/2023] Open
Abstract
The current study was initiated when our specific-pathogen-free laboratory toms developed unexpectedly high levels of cross-reactive antibodies to human SARS-CoV-2 (SCoV2) receptor binding domain (RBD) upon mating with feline coronavirus (FCoV)-positive queens. Multi-sequence alignment analyses of SCoV2 Wuhan RBD and four strains each from FCoV serotypes 1 and 2 (FCoV1 and FCoV2) demonstrated an amino acid sequence identity of 11.5% and a similarity of 31.8% with FCoV1 RBD (12.2% identity and 36.5% similarity for FCoV2 RBD). The sera from toms and queens cross-reacted with SCoV2 RBD and reacted with FCoV1 RBD and FCoV2 spike-2, nucleocapsid, and membrane proteins, but not with FCoV2 RBD. Thus, the queens and toms were infected with FCoV1. Additionally, the plasma from six FCoV2-inoculated cats reacted with FCoV2 and SCoV2 RBDs, but not with FCoV1 RBD. Hence, the sera from both FCoV1-infected cats and FCoV2-infected cats developed cross-reactive antibodies to SCoV2 RBD. Furthermore, eight group-housed laboratory cats had a range of serum cross-reactivity to SCoV2 RBD even 15 months later. Such cross-reactivity was also observed in FCoV1-positive group-housed pet cats. The SCoV2 RBD at a high non-toxic dose and FCoV2 RBD at a 60–400-fold lower dose blocked the in vitro FCoV2 infection, demonstrating their close structural conformations essential as vaccine immunogens. Remarkably, such cross-reactivity was also detected by the peripheral blood mononuclear cells of FCoV1-infected cats. The broad cross-reactivity between human and feline RBDs provides essential insights into developing a pan-CoV vaccine.
Collapse
Affiliation(s)
- Janet Yamamoto
- Department of Comparative, Diagnostic, and Population Medicine (CDPM), College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
- Laboratories of Comparative Immunology & Virology for Companion Animals, CDPM, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Lekshmi Edison
- Department of Comparative, Diagnostic, and Population Medicine (CDPM), College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
- Laboratories of Comparative Immunology & Virology for Companion Animals, CDPM, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Dawne Rowe-Haas
- Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
| | - Tomomi Takano
- Laboratory of Veterinary Infectious Disease, Department of Veterinary Medicine, Kitasato University, Tokyo 108-8641, Japan
| | - Chen Gilor
- Department of Small Animal Clinical Science, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Chiquitha Crews
- Department of Small Animal Clinical Science, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Apichai Tuanyok
- Laboratories of Comparative Immunology & Virology for Companion Animals, CDPM, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
- Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Ananta Arukha
- Department of Comparative, Diagnostic, and Population Medicine (CDPM), College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Sayaka Shiomitsu
- Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Heather Walden
- Department of Comparative, Diagnostic, and Population Medicine (CDPM), College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Tsutomu Hohdatsu
- Laboratory of Veterinary Infectious Disease, Department of Veterinary Medicine, Kitasato University, Tokyo 108-8641, Japan
| | - Stephen Tompkins
- Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
| | - John Morris
- Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA
| | - Bikash Sahay
- Laboratories of Comparative Immunology & Virology for Companion Animals, CDPM, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
- Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Subhashinie Kariyawasam
- Department of Comparative, Diagnostic, and Population Medicine (CDPM), College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
- Laboratories of Comparative Immunology & Virology for Companion Animals, CDPM, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| |
Collapse
|
9
|
Wang QS, Edahiro R, Namkoong H, Hasegawa T, Shirai Y, Sonehara K, Tanaka H, Lee H, Saiki R, Hyugaji T, Shimizu E, Katayama K, Kanai M, Naito T, Sasa N, Yamamoto K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Ichikawa M, Nakamura A, Harada S, Sandhu Y, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagimoto S, Noguchi Y, Yamano Y, Sasano H, Ota S, Nakamori Y, Yoshiya K, Saito F, Yoshihara T, Wada D, Iwamura H, Kanayama S, Maruyama S, Yoshiyama T, Ohta K, Kokuto H, Ogata H, Tanaka Y, Arakawa K, Shimoda M, Osawa T, Tateno H, Hase I, Yoshida S, Suzuki S, Kawada M, Horinouchi H, Saito F, Mitamura K, Hagihara M, Ochi J, Uchida T, Baba R, Arai D, Ogura T, Takahashi H, Hagiwara S, Nagao G, Konishi S, Nakachi I, Murakami K, Yamada M, Sugiura H, Sano H, Matsumoto S, Kimura N, Ono Y, Baba H, Suzuki Y, Nakayama S, Masuzawa K, Namba S, Shiroyama T, Noda Y, Niitsu T, Adachi Y, Enomoto T, Amiya S, Hara R, Yamaguchi Y, Murakami T, Kuge T, Matsumoto K, Yamamoto Y, Yamamoto M, Yoneda M, Tomono K, Kato K, Hirata H, Takeda Y, Koh H, Manabe T, Funatsu Y, Ito F, Fukui T, Shinozuka K, Kohashi S, Miyazaki M, Shoko T, Kojima M, Adachi T, Ishikawa M, Takahashi K, Inoue T, Hirano T, Kobayashi K, Takaoka H, Watanabe K, Miyazawa N, Kimura Y, Sado R, Sugimoto H, Kamiya A, Kuwahara N, Fujiwara A, Matsunaga T, Sato Y, Okada T, Hirai Y, Kawashima H, Narita A, Niwa K, Sekikawa Y, Nishi K, Nishitsuji M, Tani M, Suzuki J, Nakatsumi H, Ogura T, Kitamura H, Hagiwara E, Murohashi K, Okabayashi H, Mochimaru T, Nukaga S, Satomi R, Oyamada Y, Mori N, Baba T, Fukui Y, Odate M, Mashimo S, Makino Y, Yagi K, Hashiguchi M, Kagyo J, Shiomi T, Fuke S, Saito H, Tsuchida T, Fujitani S, Takita M, Morikawa D, Yoshida T, Izumo T, Inomata M, Kuse N, Awano N, Tone M, Ito A, Nakamura Y, Hoshino K, Maruyama J, Ishikura H, Takata T, Odani T, Amishima M, Hattori T, Shichinohe Y, Kagaya T, Kita T, Ohta K, Sakagami S, Koshida K, Hayashi K, Shimizu T, Kozu Y, Hiranuma H, Gon Y, Izumi N, Nagata K, Ueda K, Taki R, Hanada S, Kawamura K, Ichikado K, Nishiyama K, Muranaka H, Nakamura K, Hashimoto N, Wakahara K, Koji S, Omote N, Ando A, Kodama N, Kaneyama Y, Maeda S, Kuraki T, Matsumoto T, Yokote K, Nakada TA, Abe R, Oshima T, Shimada T, Harada M, Takahashi T, Ono H, Sakurai T, Shibusawa T, Kimizuka Y, Kawana A, Sano T, Watanabe C, Suematsu R, Sageshima H, Yoshifuji A, Ito K, Takahashi S, Ishioka K, Nakamura M, Masuda M, Wakabayashi A, Watanabe H, Ueda S, Nishikawa M, Chihara Y, Takeuchi M, Onoi K, Shinozuka J, Sueyoshi A, Nagasaki Y, Okamoto M, Ishihara S, Shimo M, Tokunaga Y, Kusaka Y, Ohba T, Isogai S, Ogawa A, Inoue T, Fukuyama S, Eriguchi Y, Yonekawa A, Kan-o K, Matsumoto K, Kanaoka K, Ihara S, Komuta K, Inoue Y, Chiba S, Yamagata K, Hiramatsu Y, Kai H, Asano K, Oguma T, Ito Y, Hashimoto S, Yamasaki M, Kasamatsu Y, Komase Y, Hida N, Tsuburai T, Oyama B, Takada M, Kanda H, Kitagawa Y, Fukuta T, Miyake T, Yoshida S, Ogura S, Abe S, Kono Y, Togashi Y, Takoi H, Kikuchi R, Ogawa S, Ogata T, Ishihara S, Kanehiro A, Ozaki S, Fuchimoto Y, Wada S, Fujimoto N, Nishiyama K, Terashima M, Beppu S, Yoshida K, Narumoto O, Nagai H, Ooshima N, Motegi M, Umeda A, Miyagawa K, Shimada H, Endo M, Ohira Y, Watanabe M, Inoue S, Igarashi A, Sato M, Sagara H, Tanaka A, Ohta S, Kimura T, Shibata Y, Tanino Y, Nikaido T, Minemura H, Sato Y, Yamada Y, Hashino T, Shinoki M, Iwagoe H, Takahashi H, Fujii K, Kishi H, Kanai M, Imamura T, Yamashita T, Yatomi M, Maeno T, Hayashi S, Takahashi M, Kuramochi M, Kamimaki I, Tominaga Y, Ishii T, Utsugi M, Ono A, Tanaka T, Kashiwada T, Fujita K, Saito Y, Seike M, Watanabe H, Matsuse H, Kodaka N, Nakano C, Oshio T, Hirouchi T, Makino S, Egi M, Omae Y, Nannya Y, Ueno T, Takano T, Katayama K, Ai M, Kumanogoh A, Sato T, Hasegawa N, Tokunaga K, Ishii M, Koike R, Kitagawa Y, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K, Okada Y. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force. Nat Commun 2022; 13:4830. [PMID: 35995775 PMCID: PMC9395416 DOI: 10.1038/s41467-022-32276-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 07/25/2022] [Indexed: 11/12/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has caused millions of deaths, where comprehensive understanding of disease mechanisms is still unestablished. In particular, studies of gene expression dynamics and regulation landscape in COVID-19 infected individuals are limited. Here, we report on a thorough analysis of whole blood RNA-seq data from 465 genotyped samples from the Japan COVID-19 Task Force, including 359 severe and 106 non-severe COVID-19 cases. We discover 1169 putative causal expression quantitative trait loci (eQTLs) including 34 possible colocalizations with biobank fine-mapping results of hematopoietic traits in a Japanese population, 1549 putative causal splice QTLs (sQTLs; e.g. two independent sQTLs at TOR1AIP1), as well as biologically interpretable trans-eQTL examples (e.g., REST and STING1), all fine-mapped at single variant resolution. We perform differential gene expression analysis to elucidate 198 genes with increased expression in severe COVID-19 cases and enriched for innate immune-related functions. Finally, we evaluate the limited but non-zero effect of COVID-19 phenotype on eQTL discovery, and highlight the presence of COVID-19 severity-interaction eQTLs (ieQTLs; e.g., CLEC4C and MYBL2). Our study provides a comprehensive catalog of whole blood regulatory variants in Japanese, as well as a reference for transcriptional landscapes in response to COVID-19 infection. Genetic mechanisms influencing COVID-19 susceptibility are not well understood. Here, the authors analyzed whole blood RNA-seq data of 465 Japanese individuals with COVID-19, highlighting thousands of fine-mapped variants affecting expression and splicing of genes, as well as the presence of COVID-19 severity-interaction eQTLs.
Collapse
|
10
|
Takano T, Ryu M, Doki T, Kusuhara H. Immunodominant B-Cell Linear Epitope on the VP1 P Domain of a Feline Norovirus Cat Model. Pathogens 2022; 11:pathogens11070731. [PMID: 35889977 PMCID: PMC9316177 DOI: 10.3390/pathogens11070731] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/21/2022] [Accepted: 06/24/2022] [Indexed: 11/21/2022] Open
Abstract
Norovirus (NoV) infection remains a major public health concern worldwide. Appropriate animal models are essential for the development of effective NoV vaccines. We previously established the feline NoV (FNoV)-cat model as a surrogate animal model for human NoV infection. In the present study, we analyzed the B-cell linear epitope in the P domain of FNoV to confirm the basic immunological features of the FNoV-cat model. B-cell linear epitopes were present in the P2 subdomain. We compared antibody levels to peptides containing the B-cell linear epitope (P-10) in three FNoV-infected cats with time-course changes in viral load and symptom scoring. After FNoV infection, viral shedding and clinical symptoms were shown to improve by elevated levels of antibodies against P-10 in the plasma. This report provides important information for understanding NoV infections in humans and cats.
Collapse
Affiliation(s)
- Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada 34-8628, Japan; (M.R.); (T.D.)
- Correspondence:
| | - Mizuki Ryu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada 34-8628, Japan; (M.R.); (T.D.)
| | - Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada 34-8628, Japan; (M.R.); (T.D.)
| | - Hajime Kusuhara
- Health and Environment Research Institute, Yokkaichi 512-1211, Japan;
| |
Collapse
|
11
|
Ciesielski HM, Nishida H, Takano T, Fukuhara A, Otani T, Ikegawa Y, Okada M, Nishimura T, Furuse M, Yoo SK. Erebosis, a new cell death mechanism during homeostatic turnover of gut enterocytes. PLoS Biol 2022; 20:e3001586. [PMID: 35468130 PMCID: PMC9037934 DOI: 10.1371/journal.pbio.3001586] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 02/28/2022] [Indexed: 11/18/2022] Open
Abstract
Many adult tissues are composed of differentiated cells and stem cells, each working in a coordinated manner to maintain tissue homeostasis during physiological cell turnover. Old differentiated cells are believed to typically die by apoptosis. Here, we discovered a previously uncharacterized, new phenomenon, which we name erebosis based on the ancient Greek word erebos (“complete darkness”), in the gut enterocytes of adult Drosophila. Cells that undergo erebosis lose cytoskeleton, cell adhesion, organelles and fluorescent proteins, but accumulate Angiotensin-converting enzyme (Ance). Their nuclei become flat and occasionally difficult to detect. Erebotic cells do not have characteristic features of apoptosis, necrosis, or autophagic cell death. Inhibition of apoptosis prevents neither the gut cell turnover nor erebosis. We hypothesize that erebosis is a cell death mechanism for the enterocyte flux to mediate tissue homeostasis in the gut. It has been believed that gut enterocytes continuously die through apoptosis. However, this study shows that gut enterocytes die through a novel cell death mechanism, named erebosis. Erobotic cells lack the characteristic features of apoptotic, necrotic or autophagic cell death; instead they lose their cytoskeleton, cell adhesion and organelles, and their nuclei become flat and indistinct.
Collapse
Affiliation(s)
- Hanna M. Ciesielski
- Division of Developmental Biology and Regenerative Medicine, Kobe University, Kobe, Japan
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
| | - Hiroshi Nishida
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Division of Cell Physiology, Kobe University, Kobe, Japan
| | - Tomomi Takano
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
| | - Aya Fukuhara
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Graduate School of Biostudies, Kyoto University, Kyoto, Japan
| | - Tetsuhisa Otani
- Division of Cell structure, National Institute for Physiological Sciences, Okazaki, Japan
- Department of Physiological Sciences, School of Life Science, SOKENDAI, Okazaki, Japan
| | - Yuko Ikegawa
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- Graduate School of Biostudies, Kyoto University, Kyoto, Japan
| | - Morihiro Okada
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
| | - Takashi Nishimura
- Metabolic Regulation and Genetics, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan
| | - Mikio Furuse
- Division of Cell structure, National Institute for Physiological Sciences, Okazaki, Japan
- Department of Physiological Sciences, School of Life Science, SOKENDAI, Okazaki, Japan
| | - Sa Kan Yoo
- Division of Developmental Biology and Regenerative Medicine, Kobe University, Kobe, Japan
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- * E-mail:
| |
Collapse
|
12
|
Doki T, Takahashi K, Hasegawa N, Takano T. In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus. Res Vet Sci 2022; 144:27-33. [PMID: 35033848 PMCID: PMC8739810 DOI: 10.1016/j.rvsc.2022.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 12/28/2021] [Accepted: 01/05/2022] [Indexed: 11/30/2022]
Abstract
Feline infectious peritonitis virus (FIPV: virulent feline coronavirus) causes a fatal disease called feline infectious peritonitis (FIP) in wild and domestic cat species. Recent studies identified several antiviral drugs that are effective against FIPV. Drug combination is one of the important strategies in the development of novel treatments for viral infections. GS-441524, a nucleoside analog, and itraconazole, a triazole antifungal drug, have been reported that have antiviral effect against FIPV. This study aims to investigate whether the combination of GS-441524 and itraconazole has synergic antiviral effect against FIPV. The antiviral effect was measured by plaque reduction assay using felis catus whole fatus-4 cell. The plaque reduction of GS-441524 against type I FIPVs increased as the concentration of itraconazole increased. The similar result was obtained for type II FIPV. In addition, the calculated combination index (CI) demonstrated that there was a strong synergy between GS-441524 and itraconazole. It is concluded that the combination of GS-441524 and itraconazole may enhance the individual effect of each drug against replication of type I FIPVs and may contribute to development more effective treatment strategy for FIP.
Collapse
Affiliation(s)
- Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.
| | - Ken Takahashi
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Nobuhisa Hasegawa
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.
| | - Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.
| |
Collapse
|
13
|
Haga K, Takai-Todaka R, Matsumura Y, Song C, Takano T, Tojo T, Nagami A, Ishida Y, Masaki H, Tsuchiya M, Ebisudani T, Sugimoto S, Sato T, Yasuda H, Fukunaga K, Sawada A, Nemoto N, Murata K, Morimoto T, Katayama K. Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model. PLoS Pathog 2021; 17:e1009542. [PMID: 34648602 PMCID: PMC8516304 DOI: 10.1371/journal.ppat.1009542] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 09/10/2021] [Indexed: 12/23/2022] Open
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the disease COVID-19 can lead to serious symptoms, such as severe pneumonia, in the elderly and those with underlying medical conditions. While vaccines are now available, they do not work for everyone and therapeutic drugs are still needed, particularly for treating life-threatening conditions. Here, we showed nasal delivery of a new, unmodified camelid single-domain antibody (VHH), termed K-874A, effectively inhibited SARS-CoV-2 titers in infected lungs of Syrian hamsters without causing weight loss and cytokine induction. In vitro studies demonstrated that K-874A neutralized SARS-CoV-2 in both VeroE6/TMPRSS2 and human lung-derived alveolar organoid cells. Unlike other drug candidates, K-874A blocks viral membrane fusion rather than viral attachment. Cryo-electron microscopy revealed K-874A bound between the receptor binding domain and N-terminal domain of the virus S protein. Further, infected cells treated with K-874A produced fewer virus progeny that were less infective. We propose that direct administration of K-874A to the lung could be a new treatment for preventing the reinfection of amplified virus in COVID-19 patients.
Collapse
Affiliation(s)
- Kei Haga
- Laboratory of Viral Infection, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
| | - Reiko Takai-Todaka
- Laboratory of Viral Infection, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
| | - Yuta Matsumura
- Safety Science Laboratories, Kao Corporation, Tokyo, Japan
| | - Chihong Song
- Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Japan
- National Institute for Physiological Sciences, Okazaki, Japan
| | - Tomomi Takano
- School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Takuto Tojo
- Biological Science Laboratories, Kao Corporation, Wakayama, Japan
| | - Atsushi Nagami
- Safety Science Laboratories, Kao Corporation, Tokyo, Japan
| | - Yuki Ishida
- Safety Science Laboratories, Kao Corporation, Tokyo, Japan
| | | | | | - Toshiki Ebisudani
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo, Japan
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Shinya Sugimoto
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Toshiro Sato
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Hiroyuki Yasuda
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Koichi Fukunaga
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Akihito Sawada
- Laboratory of Viral Infection, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
| | - Naoto Nemoto
- Epsilon Molecular Engineering Inc., Saitama, Japan
| | - Kazuyoshi Murata
- Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Japan
- National Institute for Physiological Sciences, Okazaki, Japan
| | | | - Kazuhiko Katayama
- Laboratory of Viral Infection, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
- * E-mail:
| |
Collapse
|
14
|
Takano T, Hamaguchi S, Hasegawa N, Doki T, Soma T. Predominance of canine parvovirus 2b in Japan: an epidemiological study during 2014-2019. Arch Virol 2021; 166:3151-3156. [PMID: 34387749 DOI: 10.1007/s00705-021-05200-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 06/16/2021] [Indexed: 10/20/2022]
Abstract
Canine parvovirus 2 (CPV-2) is an important pathogen of domestic dogs and wild canids. In Japan, CPV-2 infection is one of the most common infectious diseases of dogs. We analyzed samples collected between 2014 and 2019 to identify antigenic variants of CPV-2 in dogs in Japan. Our results demonstrated that the CPV-2b variant was predominant. The CPV-2c variant was not found among our samples. Our findings demonstrate that the distribution of CPV-2 antigenic variants in Japan was more similar to that in Australia than to that in neighboring countries in Asia.
Collapse
Affiliation(s)
- Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan.
| | - Shun Hamaguchi
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan
| | - Nobuhisa Hasegawa
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan
| | - Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan
| | - Takehisa Soma
- Veterinary Diagnostic Laboratory, Marupi Lifetech Co., Ltd, Fushio-cho, Ikeda, Osaka, 563-0011, Japan
| |
Collapse
|
15
|
Nishida H, Okada M, Yang L, Takano T, Tabata S, Soga T, Ho DM, Chung J, Minami Y, Yoo SK. Methionine restriction breaks obligatory coupling of cell proliferation and death by an oncogene Src in Drosophila. eLife 2021; 10:59809. [PMID: 33902813 PMCID: PMC8079150 DOI: 10.7554/elife.59809] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 04/02/2021] [Indexed: 12/16/2022] Open
Abstract
Oncogenes often promote cell death as well as proliferation. How oncogenes drive these diametrically opposed phenomena remains to be solved. A key question is whether cell death occurs as a response to aberrant proliferation signals or through a proliferation-independent mechanism. Here, we reveal that Src, the first identified oncogene, simultaneously drives cell proliferation and death in an obligatorily coupled manner through parallel MAPK pathways. The two MAPK pathways diverge from a lynchpin protein Slpr. A MAPK p38 drives proliferation whereas another MAPK JNK drives apoptosis independently of proliferation signals. Src-p38-induced proliferation is regulated by methionine-mediated Tor signaling. Reduction of dietary methionine uncouples the obligatory coupling of cell proliferation and death, suppressing tumorigenesis and tumor-induced lethality. Our findings provide an insight into how cells evolved to have a fail-safe mechanism that thwarts tumorigenesis by the oncogene Src. We also exemplify a diet-based approach to circumvent oncogenesis by exploiting the fail-safe mechanism.
Collapse
Affiliation(s)
- Hiroshi Nishida
- Division of Cell Physiology, Kobe University, Kobe, Japan.,RIKEN CPR, Kobe, Japan
| | | | | | | | - Sho Tabata
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan
| | - Tomoyoshi Soga
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan
| | - Diana M Ho
- Harvard Medical School, Boston, United States
| | | | | | - Sa Kan Yoo
- RIKEN CPR, Kobe, Japan.,RIKEN BDR, Kobe, Japan.,Division of Developmental Biology and Regenerative Medicine, Kobe University, Kobe, Japan
| |
Collapse
|
16
|
Sasaki A, Nishimura T, Takano T, Naito S, Yoo SK. white regulates proliferative homeostasis of intestinal stem cells during ageing in Drosophila. Nat Metab 2021; 3:546-557. [PMID: 33820991 DOI: 10.1038/s42255-021-00375-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Accepted: 02/25/2021] [Indexed: 12/19/2022]
Abstract
Tissue integrity is contingent on maintaining stem cells. Intestinal stem cells (ISCs) over-proliferate during ageing, leading to tissue dysplasia in Drosophila melanogaster. Here we describe a role for white, encoding the evolutionarily conserved ATP-binding cassette transporter subfamily G, with a particularly well-characterized role in eye colour pigmentation, in ageing-induced ISC proliferation in the midgut. ISCs increase expression of white during ageing. ISC-specific inhibition of white suppresses ageing-induced ISC dysregulation and prolongs lifespan. Of the proteins that form heterodimers with White, Brown mediates ISC dysregulation during ageing. Metabolomics analyses reveal previously unappreciated, profound metabolic impacts of white inhibition on organismal metabolism. Among the metabolites affected by White, tetrahydrofolate is transported by White, is accumulated in ISCs during ageing and is indispensable for ageing-induced ISC over-proliferation. Since Thomas Morgan's isolation of a white mutant as the first Drosophila mutant, white mutants have been used extensively as genetic systems and often as controls. Our findings provide insights into metabolic regulation of stem cells mediated by the classic gene white.
Collapse
Affiliation(s)
- Ayaka Sasaki
- Graduate School of Science and Technology, Kwansei Gakuin University, Sanda, Japan
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
| | | | - Tomomi Takano
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
| | - Saki Naito
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan
- Graduate School of Frontier Biosciences, Osaka University, Suita, Japan
| | - Sa Kan Yoo
- Graduate School of Science and Technology, Kwansei Gakuin University, Sanda, Japan.
- Physiological Genetics Laboratory, RIKEN CPR, Kobe, Japan.
- Laboratory for Homeodynamics, RIKEN BDR, Kobe, Japan.
| |
Collapse
|
17
|
Takano T, Watanabe H, Doki T, Kusuhara H. Detection of feline norovirus using commercial real-time RT-PCR kit for the diagnosis of human norovirus infection. J Vet Med Sci 2021; 83:805-808. [PMID: 33692232 PMCID: PMC8182310 DOI: 10.1292/jvms.20-0703] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Feline noroviruses (FNoVs) are potential clinical pathogens in cats. To perform an epidemiological study of FNoV infection, it is necessary to develop a simple and effective method for virus detection. We investigated whether a commercial human NoV quantitative RT-PCR kit for the detection of human NoVs used in medical practice can be applied for FNoV detection. This kit was capable of detecting the FNoV gene regardless of the genogroup (GIV and GVI) in experimental and field samples. Based on the above findings, it is possible to detect FNoVs using human NoV tests. The relationship between FNoV infection and gastroenteritis in cats may be clarified by applying these methods to an epidemiological survey of FNoVs.
Collapse
Affiliation(s)
- Tomomi Takano
- School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Haruna Watanabe
- School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Tomoyoshi Doki
- School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Hajime Kusuhara
- Health and Environment Research Institute, Yokkaichi, Mie 512-1211, Japan
| |
Collapse
|
18
|
Takano T, Satoh K, Doki T. Possible Antiviral Activity of 5-Aminolevulinic Acid in Feline Infectious Peritonitis Virus (Feline Coronavirus) Infection. Front Vet Sci 2021; 8:647189. [PMID: 33644160 PMCID: PMC7903937 DOI: 10.3389/fvets.2021.647189] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Accepted: 01/20/2021] [Indexed: 11/13/2022] Open
Abstract
Feline infectious peritonitis (FIP) is a life-threatening infectious disease of cats caused by virulent feline coronavirus (FIP virus: FIPV). For the treatment of FIP, several effective antivirals were recently reported, but many of these are not available for practical use. 5-amino levulinic acid (5-ALA) is a low-molecular-weight amino acid synthesized in plant and animal cells. 5-ALA can be synthesized in a large amount, and it is widely applied in the medical and agricultural fields. We hypothesized that 5-ALA inhibits FIPV infection. Therefore, we evaluated its antiviral activity against FIPV in felis catus whole fetus-4 cells and feline primary macrophages. FIPV infection was significantly inhibited by 250 μM 5-ALA. Our study suggested that 5-ALA is applicable for the treatment and prevention of FIPV infection.
Collapse
Affiliation(s)
- Tomomi Takano
- Laboratory of Veterinary Infectious Disease, Department of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Kumi Satoh
- Laboratory of Veterinary Infectious Disease, Department of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, Department of Veterinary Medicine, Kitasato University, Towada, Japan
| |
Collapse
|
19
|
Sun Q, Yamada T, Han Y, Takano T. Influence of salt stress on C 4 photosynthesis in Miscanthus sinensis Anderss. Plant Biol (Stuttg) 2021; 23:44-56. [PMID: 33030790 DOI: 10.1111/plb.13192] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 09/23/2020] [Accepted: 09/24/2020] [Indexed: 06/11/2023]
Abstract
Miscanthus sinensis Anderss. is a good candidate for C4 bioenergy crop development for marginal lands. As one of the characteristics of marginal lands, salinization is a major limitation to agricultural production. The present work aimed to investigate the possible factors involved in the tolerance of M. sinensis C4 photosynthesis to salinity stress. Seedlings of two accessions (salt-tolerant 'JM0119' and salt-sensitive 'JM0099') were subjected to 0 mm NaCl (control) or 250 mm NaCl (salt stress treatment) for 2 weeks. The chlorophyll content, parameters of photosynthesis and chlorophyll a fluorescence, activity of C4 enzymes and expression of C4 genes were measured. The results showed that photosynthesis rate, transpiration rate, chlorophyll content, PSII operating efficiency, coefficient of photochemical quenching, activity of phosphoenolpyruvate carboxylase (PEPC) and pyruvate, orthophosphate dikinase (PPDK) and gene expression of PEPC and PPDK under salinity were higher after long-term salinity exposure in 'JM0119' than in 'JM0099', while activity of NADP-malate dehydrogenase (NADP-MDH) and NADP-malic enzyme (NADP-ME), together with expression of NADP-MDH and NADP-ME, were much higher in 'JM0099' than in 'JM0119'. In conclusion, the increased photosynthetic capacity under long-term salt stress in the salt-tolerant relative to the salt-sensitive M. sinensis accession was mainly associated with non-stomatal factors, such as reduced chlorophyll loss, higher PSII operating efficiency, enhanced activity of PEPC and PPDK and relatively lower activity of NADP-ME.
Collapse
Affiliation(s)
- Q Sun
- Asian Natural Environmental Science Center (ANESC), The University of Tokyo, Tokyo, Japan
- College of Health Science and Environmental Engineering, Shenzhen Technology University, Shenzhen, Guangdong, China
| | - T Yamada
- Field Science Center for Northern Biosphere, Hokkaido University, Sapporo, Hokkaido, Japan
| | - Y Han
- College of Health Science and Environmental Engineering, Shenzhen Technology University, Shenzhen, Guangdong, China
| | - T Takano
- Asian Natural Environmental Science Center (ANESC), The University of Tokyo, Tokyo, Japan
| |
Collapse
|
20
|
Imanishi A, Aoki Y, Kakehi M, Mori S, Takano T, Kubota Y, Kim HS, Shibata Y, Nishiwaki K. Genetic interactions among ADAMTS metalloproteases and basement membrane molecules in cell migration in Caenorhabditis elegans. PLoS One 2020; 15:e0240571. [PMID: 33264296 PMCID: PMC7710118 DOI: 10.1371/journal.pone.0240571] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 11/10/2020] [Indexed: 11/18/2022] Open
Abstract
During development of the Caenorhabditis elegans gonad, the gonadal leader cells, called distal tip cells (DTCs), migrate in a U-shaped pattern to form the U-shaped gonad arms. The ADAMTS (adisintegrin and metalloprotease with thrombospondin motifs) family metalloproteases MIG-17 and GON-1 are required for correct DTC migration. Mutations in mig-17 result in misshapen gonads due to the misdirected DTC migration, and mutations in gon-1 result in shortened and swollen gonads due to the premature termination of DTC migration. Although the phenotypes shown by mig-17 and gon-1 mutants are very different from one another, mutations that result in amino acid substitutions in the same basement membrane protein genes, emb-9/collagen IV α1, let-2/collagen IV α2 and fbl-1/fibulin-1, were identified as genetic suppressors of mig-17 and gon-1 mutants. To understand the roles shared by these two proteases, we examined the effects of the mig-17 suppressors on gon-1 and the effects of the gon-1 suppressors and enhancers on mig-17 gonadal defects. Some of the emb-9, let-2 and fbl-1 mutations suppressed both mig-17 and gon-1, whereas others acted only on mig-17 or gon-1. These results suggest that mig-17 and gon-1 have their specific functions as well as functions commonly shared between them for gonad formation. The levels of collagen IV accumulation in the DTC basement membrane were significantly higher in the gon-1 mutants as compared with wild type and were reduced to the wild-type levels when combined with suppressor mutations, but not with enhancer mutations, suggesting that the ability to reduce collagen IV levels is important for gon-1 suppression.
Collapse
Affiliation(s)
- Ayaka Imanishi
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Yuma Aoki
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Masaki Kakehi
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Shunsuke Mori
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Tomomi Takano
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Yukihiko Kubota
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Hon-Song Kim
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Yukimasa Shibata
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| | - Kiyoji Nishiwaki
- Department of Bioscience, Kwansei Gakuin University, Sanda, Japan
| |
Collapse
|
21
|
Kameshima S, Kimura Y, Doki T, Takano T, Park CH, Itoh N. Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis. J Vet Med Sci 2020; 82:1492-1496. [PMID: 32848107 PMCID: PMC7653327 DOI: 10.1292/jvms.20-0049] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
A 3-month-old male Scottish Fold kitten with pleural fluid and low ratio of albumin to globulin (A/G ratio) was brought to our small animal hospital. Since RNA from the type I feline coronavirus (FCoV) were detected in drained pleural fluid, the cat was tentatively diagnosed with effusive feline infectious peritonitis (FIP). Following the administration of itraconazole and prednisolone, the A/G ratio increased, and the pleural fluid mostly disappeared. The fecal FCoV levels temporarily decreased. However, the cat showed neurological manifestations and was eventually euthanized due to status epilepticus after 38 days of treatment. In conclusion, itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole in FIP treatment is warranted.
Collapse
Affiliation(s)
- Satoshi Kameshima
- Laboratory of Small Animal Internal Medicine 1, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Yuya Kimura
- Laboratory of Small Animal Internal Medicine 1, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Chun-Ho Park
- Laboratory of Veterinary Pathology, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Naoyuki Itoh
- Laboratory of Small Animal Internal Medicine 1, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| |
Collapse
|
22
|
Doki T, Toda M, Hasegawa N, Hohdatsu T, Takano T. Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis. Arch Virol 2020; 165:1197-1206. [PMID: 32236683 PMCID: PMC7110289 DOI: 10.1007/s00705-020-04605-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Accepted: 03/04/2020] [Indexed: 12/18/2022]
Abstract
Feline infectious peritonitis (FIP) is a fatal disease in wild and domestic cat species. Although several drugs are expected to be useful as treatments for FIP, no drugs are available in clinical practice. In this study, we evaluated the therapeutic effect of combined use of adalimumab (an anti-human-TNF-alpha monoclonal antibody, ADA) and itraconazole (ICZ), which are presently available to veterinarians. The neutralizing activity of ADA against fTNF-alpha-induced cytotoxicity was measured in WEHI-164 cells. Ten specific pathogen-free (SPF) cats were inoculated intraperitoneally with type I FIPV KU-2. To the cats that developed FIP, ADA (10 mg/animal) was administered twice between day 0 and day 4 after the start of treatment. ICZ (50 mg/head, SID) was orally administered daily from day 0 after the start of treatment. ADA demonstrated dose-dependent neutralizing activity against rfTNF-alpha. In an animal experiment, 2 of 3 cats showed improvements in FIP clinical symptoms and blood chemistry test results, an increase in the peripheral blood lymphocyte count, and a decrease in the plasma alpha 1-AGP level were observed after the beginning of treatment. One of the cats failed to respond to treatment and was euthanized, although the viral gene level in ascites temporarily decreased after the start of treatment. ADA was found to have neutralizing activity against rfTNF-alpha. The combined use of ADA and ICZ showed a therapeutic effect for experimentally induced FIP. We consider these drugs to be a treatment option until effective anti-FIPV drugs become available.
Collapse
Affiliation(s)
- Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan
| | - Masahiro Toda
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan
| | - Nobuhisa Hasegawa
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan
| | - Tsutomu Hohdatsu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan
| | - Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori, 034-8628, Japan.
| |
Collapse
|
23
|
Doki T, Tarusawa T, Hohdatsu T, Takano T. In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus. Pathogens 2020; 9:pathogens9010067. [PMID: 31963705 PMCID: PMC7169457 DOI: 10.3390/pathogens9010067] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Revised: 01/15/2020] [Accepted: 01/15/2020] [Indexed: 12/17/2022] Open
Abstract
Background: The cationic amphiphilic drug U18666A inhibits the proliferation of type I FIPV in vitro. In this study, we evaluated the in vivo antiviral effects of U18666A by administering it to SPF cats challenged with type I FIPV. Methods: Ten SPF cats were randomly assigned to two experimental groups. FIPV KU-2 were inoculated intraperitoneally to cats. The control group was administered PBS, and the U18666A-treated group was administered U18666A subcutaneously at 2.5 mg/kg on day 0, and 1.25 mg/kg on days 2 and 4 after viral inoculation. Results: Two of the five control cats administered PBS alone developed FIP. Four of the five cats administered U18666A developed no signs of FIP. One cat that temporarily developed fever, had no other clinical symptoms, and no gross lesion was noted on an autopsy after the end of the experiment. The FIPV gene was detected intermittently in feces and saliva regardless of the development of FIP or administration of U18666A. Conclusions: When U18666A was administered to cats experimentally infected with type I FIPV, the development of FIP might be suppressed compared with the control group. However, the number of animals with FIP is too low to establish anti-viral effect of U18666A in cats.
Collapse
Affiliation(s)
| | | | | | - Tomomi Takano
- Correspondence: ; Tel.: +81-176-23-4371; Fax: +81-176-23-8703
| |
Collapse
|
24
|
Takano T, Wakayama Y, Doki T. Endocytic Pathway of Feline Coronavirus for Cell Entry: Differences in Serotype-Dependent Viral Entry Pathway. Pathogens 2019; 8:pathogens8040300. [PMID: 31888266 PMCID: PMC6963708 DOI: 10.3390/pathogens8040300] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Revised: 12/15/2019] [Accepted: 12/15/2019] [Indexed: 12/30/2022] Open
Abstract
Feline coronavirus (FCoV) is a pathogen causing a lethal infectious disease in cats, feline infectious peritonitis. It has two serotypes (type I FCoV and type II FCoV). According to our previous study, type I FCoV infection is inhibited by compounds inducing intracellular cholesterol accumulation, whereas type II FCoV infection is not inhibited. Intracellular cholesterol accumulation was reported to disrupt late endosome function. Based on these findings, types I and II FCoV are considered to enter the cytosol through late and early endosomes, respectively. We investigated whether the antiviral activities of a late endosome trafficking inhibitor and cholesterol-accumulating agents are different between the FCoV serotypes. The late endosome trafficking inhibitor did not inhibit type II FCoV infection, but it inhibited type I FCoV infection. Type I FCoV infection was inhibited by cholesterol-accumulating triazoles, but not by non-cholesterol-accumulating triazoles. These phenomena were observed in both feline cell lines and feline primary macrophages. This study provides additional information on the differences in intracellular reproductive cycle between type I and type II FCoV.
Collapse
|
25
|
Kizawa R, Miura Y, Oda Y, Nagaoka Y, Masuda J, Ozaki Y, Kondoh C, Moriguchi S, Takahashi Y, Ogawa K, Hashimoto YT, Taniguchi S, Okaneya T, Kishi A, Hayashi N, Takaya H, Takano T. Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Fukano H, Takano T, Fujimoto Y, Nakatani R, Watanabe M, Hidaka Y, Shimomura I. In tube immunocytochemistry for fluorescence-activated cell sorting that prevents RNA degradation in sorted cells. Biotech Histochem 2019; 95:1-7. [PMID: 31423857 DOI: 10.1080/10520295.2019.1632485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
Fluorescence-activated cell sorting (FACS) is a powerful tool for analyzing stem cells. When using fixed cells, however, it is sometimes difficult to analyze RNA extracted from sorted cells due to RNA degradation. We established a protocol for immunocytochemistry before FACS to prevent RNA degradation. Cells were fixed with a methanol-based fixative (UM-Fix), then subjected to immunocytochemistry. The addition of RNase inhibitor and dithiothreitol (DTT) to some buffers used for immunocytochemistry increased RNA integrity after cell recovery. We found increased copy numbers of mRNA in recovered cells using quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis. When RNase inhibitor and DTT were added, amplification of mRNA using T7 promoter was possible with RNA extracted from recovered cells after FACS. Our protocol ensures high quality RNA in cells recovered by FACS; therefore, gene expression analysis with a smaller number of cells is possible using pre-amplification of mRNAs. Our protocol for immunocytochemistry also might be applicable to RNA recovery after immunostaining.
Collapse
Affiliation(s)
- H Fukano
- Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - T Takano
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Y Fujimoto
- Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - R Nakatani
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - M Watanabe
- Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Y Hidaka
- Department of Laboratory Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - I Shimomura
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| |
Collapse
|
27
|
Takano T, Yamada S, Doki T, Hohdatsu T. Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route. J Vet Med Sci 2019; 81:911-915. [PMID: 31019150 PMCID: PMC6612493 DOI: 10.1292/jvms.18-0702] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Feline infectious peritonitis virus (FIPV) causes a severe, immune-mediated disease called FIP in domestic and wild cats. It is unclear whether FIP transmits from cat to cat through the oral route of FIPV infection, and the reason for this includes that FIP is caused by oral inoculation with some FIPV strains (e.g., type II FIPV WSU 79-1146), but is not caused by other FIPV (e.g., type I FIPV KU-2 strain: FIPV-I KU-2). In this study, when cats passively immunized with anti-FIPV-I KU-2 antibodies were orally inoculated with FIPV-I KU-2, FIP was caused at a 50% probability, i.e., FIPV not causing FIP through oral infection caused FIP by inducing antibody-dependent enhancement. Many strains of type I FIPV do not cause FIP by inoculation through the oral route in cats. Based on the findings of this study, type I FIPV which orally infected cats may cause FIP depending on the condition.
Collapse
Affiliation(s)
- Tomomi Takano
- School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Shinji Yamada
- School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.,Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan
| | - Tomoyoshi Doki
- School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| | - Tsutomu Hohdatsu
- School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan
| |
Collapse
|
28
|
Matsumoto K, Futamura M, Miyaki T, Iwasa T, Imoto S, Doi M, Tokunaga S, Aogi K, Yoshimura K, Takano T. A phase 2 study evaluating dose dense AC (ddAC) followed by dose dense paclitaxel (ddP) supported by 3.6 mg peg-filgrastim (ddAC-ddP3.6) for patients (pts) with primary breast cancer (PBC) in Japan -WJOG9016B-. Breast 2019. [DOI: 10.1016/s0960-9776(19)30103-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
29
|
Ozaki Y, Takahashi M, Tanabe Y, Miura Y, Tamura N, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T. Atypical femoral fracture in breast cancer patients with bone metastasis receiving denosumab therapy: multi-center retrospective analysis. Breast 2019. [DOI: 10.1016/s0960-9776(19)30450-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
30
|
Ozaki Y, Kitano S, Matsumoto K, Takahashi M, Mukohara T, Futamura M, Masuda N, Tsurutani J, Yoshimura K, Minami H, Takano T. Abstract OT1-12-02: Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In recent years, anti-PD-1 antibody, an immune checkpoint inhibitor, has been developed for the treatment of various types of cancer, including breast cancer. Synergistic effects of nivolumab, paclitaxel and bevacizumab are expected, based on various preclinical data, when these drugs are administered in combination. A biomarker study is ongoing to evaluate the immune status of patients participating in the NEWBEAT trial, which is a phase II trial of nivolumab + paclitaxel + bevacizumab therapy as first-line treatment for patients with metastatic or recurrent HER2-negative breast cancer. Methods: HER2-negative breast cancer patients from the WJOG9917B (NEWBEAT) trial are enrolled in this biomarker study. To explore new biomarkers for combined treatment of breast cancer with immune-checkpoint inhibitors and anti-vascular endothelial growth factor antibodies, we propose to conduct multicolor immunohistochemistry (IHC) assays for immunomonitoring of the intra-tumor environment, such as the expressions of PD-L1, CD4 and CD8. Blood samples are collected before the start of treatment and at four time-points during the treatment, to determine, using a multicolor flow cytometry panel, the numbers of circulating immunosuppressive cells, such as regulatory T cells, myeloid-derived suppressor cells and tumor-associated macrophages (M2). In the NEWBEAT trial, patients receive nivolumab 240 mg/body on days 1 and 15, paclitaxel 90 mg/m2 on days 1, 8 and 15, and bevacizumab 10 mg/kg on days 1 and 15 every 4 weeks until disease progression. The primary endpoint is the objective response rate, and the key secondary endpoints include progression-free survival, overall survival, and toxicity of the protocol treatment. A total of 51 patients will be enrolled and the enrollment period will be one year. This trial opened to accrual in February 2018. Clinical trial registry number: UMIN000029590
Citation Format: Ozaki Y, Kitano S, Matsumoto K, Takahashi M, Mukohara T, Futamura M, Masuda N, Tsurutani J, Yoshimura K, Minami H, Takano T. Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-12-02.
Collapse
Affiliation(s)
- Y Ozaki
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - S Kitano
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - K Matsumoto
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - M Takahashi
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - T Mukohara
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - M Futamura
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - N Masuda
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - J Tsurutani
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - K Yoshimura
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - H Minami
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - T Takano
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| |
Collapse
|
31
|
Masuda N, Yamashita T, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Abstract OT2-07-05: A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel + Trastuzumab (H) + Pertuzumab (P) provided progression-free survival (PFS) and overall survival (OS) benefits in HER2-positive advanced or metastatic breast cancer (AMBC) in the CLEOPATRA study as a first-line therapy. However, long-term administration of docetaxel at a dose of 75 mg/m2 every 3 weeks in AMBC patients (pts) is difficult due to the toxicities. Eribulin mesylate (E) is a well-tolerated microtubule inhibitor, and we have reported the efficacy and safety of EHP regimen as first- and second-line therapy for AMBC in a multicenter, phase II study (JBCRG-M03/UMIN000012232). In this M06 study, we address the clinical question as to which is the better chemotherapy partner for HP as first line regimen, in terms of efficacy, toxicity and QOL.
Methods: JBCRG-M06 is a multicenter open-label randomized phase III study for HER2-positive AMBC pts who have received no prior chemotherapy except for the HER2- Antibody-Drug Conjugate (ADC). Pts will be randomized 1:1 to E (1.4mg/m2 on day 1 and 8) + H (8 mg/kg loading dose followed by 6 mg/kg) +P (840 mg loading dose followed by 420 mg) q3wks or standard taxanes (docetaxel 75mg/m2 on day1 or paclitaxel 80mg/m2 on day 1, 8 and 15) + HP q3wks. Stratification factors for randomization are; presence of visceral metastases, number of prior taxanes on perioperative adjuvant treatment, and treatment with prior anti-HER2-ADC. Primary endpoint is PFS and secondary endpoints include overall response rate, duration of response, OS, patient-reported outcomes (PRO) relating to QOL and peripheral neuropathy, new-metastases free survival, and safety. Translational research to search for biomarker for individual precision therapy will be performed. Main eligibility criteria are as follows: pts with HER2-positive AMBC, female aged 20-70 years old, ECOG PS of 0-1, LVEF ≥ 50% at baseline and adequate organ function. Pts who had progressive MBC within 6 months after the end of primary adjuvant systemic chemotherapy are excluded. The sample size was calculated by type1 error (2-sided) of 0.05 and 80% power to estimate the noninferiority margin 1.33 with an expected median PFS of 14.2 months. The target number of pts is 480 recruited over the duration of 3-years. The first patient in was achieved on August 2017. (ClinicalTrials.gov Identifier:NCT03264547).
Citation Format: Masuda N, Yamashita T, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-07-05.
Collapse
Affiliation(s)
- N Masuda
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Yamashita
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Saji
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Araki
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Ito
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Takano
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - M Takahashi
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - J Tsurutani
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Koizumi
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - M Kitada
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Kojima
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Sagara
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - H Tada
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Iwasa
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Kadoya
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Iwatani
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - H Hasegawa
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Morita
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Ohno
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| |
Collapse
|
32
|
Takano T, Akiyama M, Doki T, Hohdatsu T. Antiviral activity of itraconazole against type I feline coronavirus infection. Vet Res 2019; 50:5. [PMID: 30658691 PMCID: PMC6339390 DOI: 10.1186/s13567-019-0625-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 01/07/2019] [Indexed: 11/10/2022] Open
Abstract
Feline coronaviruses (FCoVs) are the causative agents of severe systemic disease (feline infectious peritonitis: FIP) in domestic and wild cats. FCoVs have been classified into serotypes I and II. Type I FCoV is the dominant serotype (approximately 70-90%) worldwide. Therefore, it is necessary to provide antiviral agents for type I FCoV infection. In this study, we demonstrated that itraconazole (ICZ), practically used for fungal infections in cats, inhibits the type I FCoV infection. ICZ also exhibited antiviral effect in cells after viral infection, suggesting that ICZ could potentially be used as a therapeutic.
Collapse
Affiliation(s)
- Tomomi Takano
- School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
| | - Misuzu Akiyama
- School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
| | - Tomoyoshi Doki
- School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
| | - Tsutomu Hohdatsu
- School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan.
| |
Collapse
|
33
|
Doki T, Yabe M, Takano T, Hohdatsu T. Differential induction of type I interferon by type I and type II feline coronaviruses in vitro. Res Vet Sci 2018; 120:57-62. [PMID: 30265871 PMCID: PMC7111755 DOI: 10.1016/j.rvsc.2018.09.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 08/24/2018] [Accepted: 09/17/2018] [Indexed: 12/15/2022]
Abstract
Feline infectious peritonitis (FIP) is a feline coronavirus (FCoV)-induced fatal disease in wild and domestic cats. There are two FCoV serotypes. Both type I and II FCoV can replicate in Felis catus whole fetus (fcwf)-4 cells, but the replicability of type I FCoV in feline cell lines is lower than that of type II FCoV, the reason for which is unclear. Inhibition of IFNβ production by non-structural and structural proteins, excluding spike protein has been reported in many coronavirus infections. In this study, we investigated whether IFNβ is involved in the difference in replicability in feline cell lines between types I and II FCoV. When fcwf-4 cells were infected with FCoV, the virus titer of type II FCoV in the culture supernatant was higher than that of type I FIPV. When the IFNβ expression level in FCoV-infected fcwf-4 cells was semi-quantitatively analyzed, infection with type I FIPV, excluding type I FIPV UCD-1, highly induced IFNβ expression. In contrast, induction of IFNβ by type II FCoV infection was significantly lower than that by type I FIPV. In addition, when fcwf-4 cells were adsorbed by FIPV and then stimulated with Poly(I:C), type II FCoV infection inhibited Poly(I:C)-induced IFNβ gene expression. Also, the proliferation of type I FIPV was enhanced by a IFN inhibitor. These findings clarified that, unlike type I FIPV, type II FCoV strongly inhibits IFNβ expression in infected cells. It was also suggested that the IFNβ-inducing ability is different among type I FIPV strains.
Collapse
Affiliation(s)
- Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.
| | - Midori Yabe
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.
| | - Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.
| | - Tsutomu Hohdatsu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.
| |
Collapse
|
34
|
Takano T, Yanai Y, Hiramatsu K, Doki T, Hohdatsu T. Novel single-stranded, circular DNA virus identified in cats in Japan. Arch Virol 2018; 163:3389-3393. [PMID: 30218220 PMCID: PMC7087140 DOI: 10.1007/s00705-018-4020-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 09/05/2018] [Indexed: 12/03/2022]
Abstract
We detected a novel feline stool-associated circular DNA virus (FeSCV) in fecal samples from cats with diarrhea using consensus primers matching those of circovirus and cyclovirus. FeSCV is a circular DNA virus containing a genome with a total length of 2,046 nt encoding 2 open reading frames. Phylogenetic analyses indicated that FeSCV is classified into a clade different from that of circovirus and cyclovirus. Since the FeSCVs detected in several cats in the same household had genetically similar genomes, these viruses are most likely derived from the same origin.
Collapse
Affiliation(s)
- Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Yoshitomo Yanai
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Kanae Hiramatsu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Tsutomu Hohdatsu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan.
| |
Collapse
|
35
|
Yokoe T, Hayashida T, Nagayama A, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y. Abstract P3-14-11: Comparative effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-14-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The optimal choice of antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) needs to be clarified. This study assessed the efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy (HEC).
Methods
Randomized trials that compared different antiemetic regimens were included from MEDLINE. Quality was assessed using the Cochrane risk-of-bias tool. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Data were pooled using random-effects models. We conducted indirect comparisons using network meta-analysis of a Bayesian model. The main outcomes were the odds ratio (OR) for overall complete response (CR [i.e., no emesis and no rescue]). Safety was assessed from the trial description. All statistical tests were two-sided.
Findings
We systematically reviewed 24 randomized control trials (12,104 participants), which compared 12 different antiemetic regimens. Palonosetron (PAL) 0·75 mg (PAL0·75) + dexamethasone (Dex); aprepitant (APR) + a serotonin-3 receptor antagonist (5HT3) + Dex; and APR + PAL (0·25 mg or 0·50 mg) + Dex were more favorable than the reference regimen (OR, 1·51; 95% credibility interval [95%CrI], 1·18-1·91; OR, 1·78; 95%CrI, 1·58-2·05; and OR, 2·28; 95%CrI, 1·66-3·18, respectively). The oral combination of netupitant and palonosetron (NEPA) was more effective than conventional regimens (OR, 2·39; CrI, 1·73-3·30). Olanzapine (OLZ)-containing regimens were apparently the most effective: the ORs of OLZ + 5HT3 + Dex, OLZ + PAL + Dex, and OLZ + APR + 5HT3 + Dex were 2·78, 2·58, and 4·98, respectively.
Interpretation
The regimens of PAL0·75 + Dex, APR + 5HT3 + Dex, and APR + PAL + Dex were more favorable in conventional regimens (i.e., regimens without NEPA or OLZ), which support the NCCN guideline strategy. NEPA could be a better choice than conventional regimens. OLZ-containing regimens could be an optimal choice; thus, more trials need to be accumulated.
Citation Format: Yokoe T, Hayashida T, Nagayama A, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y. Comparative effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-14-11.
Collapse
Affiliation(s)
- T Yokoe
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| | - T Hayashida
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| | - A Nagayama
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| | - T Seki
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| | - M Takahashi
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| | - T Takano
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| | - T Abe
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| | - Y Kitagawa
- Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, Japan; Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, Japan; Keio University School of Medicine, Clinical and Translational Research Center, 35 Shinanomachi, Shinjyuku, Tokyo, Japan
| |
Collapse
|
36
|
Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. Breast Cancer 2018; 25:407-415. [PMID: 29445928 PMCID: PMC5996004 DOI: 10.1007/s12282-018-0839-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 01/21/2018] [Indexed: 12/26/2022]
Abstract
Background Dual blockade of HER2 promises increased pathological complete response (pCR) rate compared with single blockade in the presence of chemotherapy for HER2-positive (+) primary breast cancer. Many questions remain regarding optimal duration of treatment and combination impact of endocrine therapy for luminal HER2 disease. Methods We designed a randomised phase II, five-arm study to evaluate the efficacy and safety of lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with/without prolongation of anti-HER2 therapy prior to chemotherapy (18 vs. 6 weeks), and with/without endocrine therapy in patients with HER2+ and/or oestrogen receptor (ER)+ disease. The primary endpoint was comprehensive pCR (CpCR) rate. Among the secondary endpoints, pCR (yT0-isyN0) rate, safety, and clinical response were evaluated. Results In total, 215 patients were enrolled; 212 were included in the full analysis set (median age 53.0 years; tumour size = T2, 65%; and tumour spread = N0, 55%). CpCR was achieved in 101 (47.9%) patients and was significantly higher in ER− patients than in ER+ patients (ER− 63.0%, ER+ 36.1%; P = 0.0034). pCR with pN0 was achieved in 42.2% of patients (ER− 57.6%, ER+ 30.3%). No significant difference was observed in pCR rate between prolonged exposure groups and standard groups. Better clinical response outcomes were obtained in the prolongation phase of the anti-HER2 therapy. No surplus was detected in pCR rate by adding endocrine treatment. No major safety concern was recognised by prolonging the anti-HER2 treatment or adding endocrine therapy. Conclusions This study confirmed the therapeutic impact of lapatinib, trastuzumab, and paclitaxel therapy for each ER− and ER+ subgroup of HER2+ patients. Development of further strategies and tools is required, particularly for luminal HER2 disease. Electronic supplementary material The online version of this article (10.1007/s12282-018-0839-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- N Masuda
- Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan
| | - M Toi
- Department of Surgery (Breast Surgery), Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
| | - N Yamamoto
- Division of Breast Surgery, Chiba Cancer Center, Chiba, Japan
| | - H Iwata
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - K Kuroi
- Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
| | - H Bando
- Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - S Ohtani
- Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - T Takano
- Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
| | - K Inoue
- Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan
| | - Y Yanagita
- Department of Breast Oncology, Gunma Prefectural Cancer Center, Gunma, Japan
| | - H Kasai
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - S Morita
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - T Sakurai
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - S Ohno
- Clinical Research Institute, NHO Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
37
|
Wan TW, Higuchi W, Khokhlova OE, Hung WC, Iwao Y, Wakayama M, Inomata N, Takano T, Lin YT, Peryanova OV, Kojima KK, Salmina AB, Teng LJ, Yamamoto T. Genomic comparison between Staphylococcus aureus GN strains clinically isolated from a familial infection case: IS1272 transposition through a novel inverted repeat-replacing mechanism. PLoS One 2017; 12:e0187288. [PMID: 29117225 PMCID: PMC5678879 DOI: 10.1371/journal.pone.0187288] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 10/17/2017] [Indexed: 01/22/2023] Open
Abstract
A bacterial insertion sequence (IS) is a mobile DNA sequence carrying only the transposase gene (tnp) that acts as a mutator to disrupt genes, alter gene expressions, and cause genomic rearrangements. "Canonical" ISs have historically been characterized by their terminal inverted repeats (IRs), which may form a stem-loop structure, and duplications of a short (non-IR) target sequence at both ends, called target site duplications (TSDs). The IS distributions and virulence potentials of Staphylococcus aureus genomes in familial infection cases are unclear. Here, we determined the complete circular genome sequences of familial strains from a Panton-Valentine leukocidin (PVL)-positive ST50/agr4 S. aureus (GN) infection of a 4-year old boy with skin abscesses. The genomes of the patient strain (GN1) and parent strain (GN3) were rich for "canonical" IS1272 with terminal IRs, both having 13 commonly-existing copies (ce-IS1272). Moreover, GN1 had a newly-inserted IS1272 (ni-IS1272) on the PVL-converting prophage, while GN3 had two copies of ni-IS1272 within the DNA helicase gene and near rot. The GN3 genome also had a small deletion. The targets of ni-IS1272 transposition were IR structures, in contrast with previous "canonical" ISs. There were no TSDs. Based on a database search, the targets for ce-IS1272 were IRs or "non-IRs". IS1272 included a larger structure with tandem duplications of the left (IRL) side sequence; tnp included minor cases of a long fusion form and truncated form. One ce-IS1272 was associated with the segments responsible for immune evasion and drug resistance. Regarding virulence, GN1 expressed cytolytic peptides (phenol-soluble modulin α and δ-hemolysin) and PVL more strongly than some other familial strains. These results suggest that IS1272 transposes through an IR-replacing mechanism, with an irreversible process unlike that of "canonical" transpositions, resulting in genomic variations, and that, among the familial strains, the patient strain has strong virulence potential based on community-associated virulence factors.
Collapse
Affiliation(s)
- Tsai-Wen Wan
- Department of Epidemiology, Genomics, and Evolution, International Medical Education and Research Center, Niigata, Japan
- Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Wataru Higuchi
- Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Olga E. Khokhlova
- Department of Epidemiology, Genomics, and Evolution, International Medical Education and Research Center, Niigata, Japan
- Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- Russia-Japan Center of Microbiology, Metagenomics and Infectious Diseases, Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Krasnoyarsk, Russia
| | - Wei-Chun Hung
- Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- Department of Microbiology and Immunology, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Yasuhisa Iwao
- Department of Epidemiology, Genomics, and Evolution, International Medical Education and Research Center, Niigata, Japan
- Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | | | | | - Tomomi Takano
- Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Yu-Tzu Lin
- Department of Epidemiology, Genomics, and Evolution, International Medical Education and Research Center, Niigata, Japan
- Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Olga V. Peryanova
- Russia-Japan Center of Microbiology, Metagenomics and Infectious Diseases, Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Krasnoyarsk, Russia
| | - Kenji K. Kojima
- Department of Life Science, National Cheng Kung University, Tainan, Taiwan
- Genetic Information Research Institute (GIRI), Mountain View, CA, United States of America
| | - Alla B. Salmina
- Research Institute of Molecular Medicine and Pathobiochemistry, Krasnoyarsk State Medical University named after Professor V.F. Vojno-Yasenetsky, Krasnoyarsk, Russia
| | - Lee-Jene Teng
- Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Tatsuo Yamamoto
- Department of Epidemiology, Genomics, and Evolution, International Medical Education and Research Center, Niigata, Japan
- Division of Bacteriology, Department of Infectious Disease Control and International Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- Russia-Japan Center of Microbiology, Metagenomics and Infectious Diseases, Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Krasnoyarsk, Russia
- * E-mail:
| |
Collapse
|
38
|
Ozaki Y, Takahashi M, Nakajima H, Ohki R, Masuda J, Kondoh C, Miura Y, Tanabe Y, Takano T. Retrospective study of atypical femoral fracture in patients with malignant bone metastasis receiving denosumab therapy: Case series. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx676.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Oki R, Kondoh C, Miura Y, Ozaki Y, Tanabe Y, Sakaguchi K, Kurosawa K, Urakami S, Okaneya T, Takano T. S-1 plus cisplatin combination therapy in patients with urachal carcinoma: A retrospective study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx661.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Iwasa T, Tsurutani J, Mizuno Y, Kojima Y, Takashima T, Matsunami N, Morimoto T, Yamamura J, Ohtani S, Tanabe Y, Watanabe S, Kato R, Tanino H, Tokunaga S, Abe H, Tsuyuki S, Hara F, Takano T, Komoike Y, Nakagawa K. Phase II trial of eribulin and S-1 combination therapy for advanced or recurrent breast cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Hu CMJ, Chang WS, Fang ZS, Chen YT, Wang WL, Tsai HH, Chueh LL, Takano T, Hohdatsu T, Chen HW. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Sci Rep 2017; 7:13043. [PMID: 29026122 PMCID: PMC5638965 DOI: 10.1038/s41598-017-13316-0] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Accepted: 09/20/2017] [Indexed: 01/09/2023] Open
Abstract
Feline infectious peritonitis (FIP), caused by a mutated feline coronavirus, is one of the most serious and fatal viral diseases in cats. The disease remains incurable, and there is no effective vaccine available. In light of the pathogenic mechanism of feline coronavirus that relies on endosomal acidification for cytoplasmic entry, a novel vacuolar ATPase blocker, diphyllin, and its nanoformulation are herein investigated for their antiviral activity against the type II feline infectious peritonitis virus (FIPV). Experimental results show that diphyllin dose-dependently inhibits endosomal acidification in fcwf-4 cells, alters the cellular susceptibility to FIPV, and inhibits the downstream virus replication. In addition, diphyllin delivered by polymeric nanoparticles consisting of poly(ethylene glycol)-block-poly(lactide-co-glycolide) (PEG-PLGA) further demonstrates an improved safety profile and enhanced inhibitory activity against FIPV. In an in vitro model of antibody-dependent enhancement of FIPV infection, diphyllin nanoparticles showed a prominent antiviral effect against the feline coronavirus. In addition, the diphyllin nanoparticles were well tolerated in mice following high-dose intravenous administration. This study highlights the therapeutic potential of diphyllin and its nanoformulation for the treatment of FIP.
Collapse
Affiliation(s)
- Che-Ming Jack Hu
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.,Research Center for Nanotechnology and Infectious Diseases, Taipei, Taiwan
| | - Wei-Shan Chang
- Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan
| | - Zih-Syun Fang
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.,Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan
| | - You-Ting Chen
- Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan
| | - Wen-Lin Wang
- Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan
| | - Hsiao-Han Tsai
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.,Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan
| | - Ling-Ling Chueh
- Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan
| | - Tomomi Takano
- School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
| | - Tsutomu Hohdatsu
- School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
| | - Hui-Wen Chen
- Research Center for Nanotechnology and Infectious Diseases, Taipei, Taiwan. .,Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
| |
Collapse
|
42
|
Kawaguchi H, Aogi K, Masuda N, Nakayama T, Ito Y, Ohtani S, Sato N, Takano T, Saji S, Tokunaga E, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka T, Morita S, Ohno S, Toi M. Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Takano T, Endoh M, Fukatsu H, Sakurada H, Doki T, Hohdatsu T. The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection. Antiviral Res 2017; 145:96-102. [PMID: 28780424 PMCID: PMC7113792 DOI: 10.1016/j.antiviral.2017.07.022] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 07/24/2017] [Accepted: 07/31/2017] [Indexed: 01/16/2023]
Abstract
Feline infectious peritonitis (FIP) is a feline coronavirus (FCoV)-induced fatal disease in wild and domestic cats. FCoV exists in two serotypes. Type I FCoV is the dominant serotype worldwide. Therefore, it is necessary to develop antiviral drugs against type I FCoV infection. We previously reported that type I FCoV is closely associated with cholesterol throughout the viral life cycle. In this study, we investigated whether U18666A, the cholesterol synthesis and transport inhibitor, shows antiviral effects against type I FCoV. U18666A induced cholesterol accumulation in cells and inhibited type I FCoV replication. Surprisingly, the antiviral activity of U18666A was suppressed by the histone deacetylase inhibitor (HDACi), Vorinostat. HDACi has been reported to revert U18666A-induced dysfunction of Niemann-Pick C1 (NPC1). In conclusion, these findings demonstrate that NPC1 plays an important role in type I FCoV infection. U18666A or other cholesterol transport inhibitor may be considered as the antiviral drug for the treatment of cats with FIP.
Collapse
Affiliation(s)
- Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Misaki Endoh
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Hiroaki Fukatsu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Haruko Sakurada
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Tsutomu Hohdatsu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan.
| |
Collapse
|
45
|
Shiraishi Y, Kohsaka S, Sato N, Goda A, Yoshikawa T, Kajimoto K, Takano T, Kitai T, Matsue Y. P1479Trends in background, management and prognosis of acute heart failure patients in Japan between 2007 to 2015: a collaborative report from ATTEND, WET-HF and REALITY-AHF registries. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Y. Shiraishi
- Keio University School of Medicine, Department of Cardiology, Tokyo, Japan
| | - S. Kohsaka
- Keio University School of Medicine, Department of Cardiology, Tokyo, Japan
| | - N. Sato
- Nippon Medical School Musashi-Kosugi Hospital, Internal Medicine, Cardiology, and Intensive Care Unit, Kanagawa, Japan
| | - A. Goda
- Kyorin University School of Medicine, Devision of Cardiology, Tokyo, Japan
| | - T. Yoshikawa
- Sakakibara Heart Institute, Department of Cardiology, Tokyo, Japan
| | - K. Kajimoto
- Sekikawa Hospital, Devision of Cardiology, Tokyo, Japan
| | - T. Takano
- Nippon Medical School, Division of Cardiovascular Medicine, Tokyo, Japan
| | - T. Kitai
- Heart and Vascular Institute, Cleveland Clinic, Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland, United States of America
| | - Y. Matsue
- University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands
| | | |
Collapse
|
46
|
Matsuyama T, Fukuda Y, Sakai T, Tanimoto N, Nakanishi M, Nakamura Y, Takano T, Nakayasu C. Clonal structure in Ichthyobacterium seriolicida, the causative agent of bacterial haemolytic jaundice in yellowtail, Seriola quinqueradiata, inferred from molecular epidemiological analysis. J Fish Dis 2017; 40:1065-1075. [PMID: 28000932 DOI: 10.1111/jfd.12586] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Revised: 10/14/2016] [Accepted: 10/17/2016] [Indexed: 06/06/2023]
Abstract
Bacterial haemolytic jaundice caused by Ichthyobacterium seriolicida has been responsible for mortality in farmed yellowtail, Seriola quinqueradiata, in western Japan since the 1980s. In this study, polymorphic analysis of I. seriolicida was performed using three molecular methods: amplified fragment length polymorphism (AFLP) analysis, multilocus sequence typing (MLST) and multiple-locus variable-number tandem repeat analysis (MLVA). Twenty-eight isolates were analysed using AFLP, while 31 isolates were examined by MLST and MLVA. No polymorphisms were identified by AFLP analysis using EcoRI and MseI, or by MLST of internal fragments of eight housekeeping genes. However, MLVA revealed variation in repeat numbers of three elements, allowing separation of the isolates into 16 sequence types. The unweighted pair group method using arithmetic averages cluster analysis of the MLVA data identified four major clusters, and all isolates belonged to clonal complexes. It is likely that I. seriolicida populations share a common ancestor, which may be a recently introduced strain.
Collapse
Affiliation(s)
- T Matsuyama
- National Research Institute of Aquaculture, Fisheries Research Agency, Research Center for Fish Diseases, Minami-Ise, Mie, Japan
| | - Y Fukuda
- Fisheries Research Institute, Oita Prefectural Agriculture, Forestry and Fisheries Research Center, Kamiura, Oita, Japan
| | - T Sakai
- National Research Institute of Aquaculture, Fisheries Research Agency, Research Center for Fish Diseases, Minami-Ise, Mie, Japan
| | - N Tanimoto
- Fisheries Technology Department, Kyoto Prefectural Agriculture, Forestry and Fisheries Technology Center, Miyazu, Kyoto, Japan
| | - M Nakanishi
- Fisheries Technology Department, Kyoto Prefectural Agriculture, Forestry and Fisheries Technology Center, Miyazu, Kyoto, Japan
| | - Y Nakamura
- National Research Institute of Fisheries Science, Fisheries Research Agency, Research Center for Bioinformatics and Biosciences, Yokohama, Kanagawa, Japan
| | - T Takano
- National Research Institute of Aquaculture, Fisheries Research Agency, Research Center for Fish Diseases, Minami-Ise, Mie, Japan
| | - C Nakayasu
- National Research Institute of Aquaculture, Fisheries Research Agency, Research Center for Fish Diseases, Minami-Ise, Mie, Japan
| |
Collapse
|
47
|
Takano T, Nakaguchi M, Doki T, Hohdatsu T. Antibody-dependent enhancement of serotype II feline enteric coronavirus infection in primary feline monocytes. Arch Virol 2017; 162:3339-3345. [PMID: 28730523 PMCID: PMC7086811 DOI: 10.1007/s00705-017-3489-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Accepted: 07/05/2017] [Indexed: 01/15/2023]
Abstract
Feline coronavirus (FCoV) has been classified into two biotypes: avirulent feline coronavirus (feline enteric coronavirus: FECV) and virulent feline coronavirus (feline infectious peritonitis virus: FIPV). In FIPV infection, antibody-dependent enhancement (ADE) has been reported and was shown to be associated with severe clinical disease. On the other hand, the potential role of ADE in FECV infection has not been examined. In this study, using laboratory strains of serotype II FIPV WSU 79-1146 (FIPV 79-1146) and serotype II FECV WSU 79-1683 (FECV 79-1683), we investigated the relationship between ADE and induction of inflammatory cytokines, which are pathogenesis-related factors, for each strain. As with ADE of FIPV 79-1146 infection, a monoclonal antibody against the spike protein of FCoV (mAb 6-4-2) enhanced FECV 79-1683 replication in U937 cells and primary feline monocytes. However, the ADE activity of FECV 79-1683 was lower than that of FIPV 79-1146. Moreover, mRNA levels of inflammatory cytokines (TNF-α, IL-1β, and IL-6) significantly increased with ADE of FIPV 79-1146 infection in primary feline monocytes, but FECV 79-1683 did not demonstrate an increase in these levels. In conclusion, infection of monocytes by FECV was enhanced by antibodies, but the efficiency of infection was lower than that of FIPV.
Collapse
Affiliation(s)
- Tomomi Takano
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Mamiko Nakaguchi
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Tomoyoshi Doki
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Tsutomu Hohdatsu
- Laboratory of Veterinary Infectious Disease, School of Veterinary Medicine, Kitasato University, Towada, Japan.
| |
Collapse
|
48
|
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.
Citation Format: Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-14.
Collapse
Affiliation(s)
- T Takano
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Tsurutani
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - M Takahashi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Yamanaka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sakai
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - Y Ito
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Fukuoka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kimura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kawabata
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Tamura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Matsumoto
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Aogi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sato
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nishio
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nakagawa
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Saeki
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| |
Collapse
|
49
|
Tsuda M, Ishiguro H, Toriguchi N, Masuda N, Bando H, Ohgami M, Homma M, Morita S, Yamamoto N, Kuroi K, Takano T, Shimizu S, Toi M. Abstract P2-11-07: Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In neoadjuvant dual HER2 blockade, over 30% of patients fail to complete treatment as planned because of lapatinib-induced diarrhea, rash, and hepatotoxicity. Lapatinib bioavailability, which affects both efficacy and toxicity, is influenced by prandial conditions.
Methods: To investigate the association between lapatinib dosage timing and toxicity, we reviewed the medical records of patients who were enrolled in the JBCRG-16/Neo-LaTH randomized phase II multicenter trial evaluating the efficacy and safety of neoadjuvant 1000 mg/day lapatinib (La) and trastuzumab (T) therapy for 6 or 12 weeks followed by 750 mg/day La, T and weekly paclitaxel for 12 weeks in Japanese patients with primary HER2 positive breast cancer. Lapatinib dosage timing was divided into three groups: after overnight fasting, between meals, and at bedtime. We also measured serum lapatinib concentrations at steady state and dosage timing on the day prior to pharmacokinetic blood sampling. The primary endpoint was to investigate the association between lapatinib dosage timing and frequency of ≥grade 2 diarrhea. The secondary endpoint was to assess the association between dosage timing and other toxicities, pharmacokinetics, efficacy, and treatment discontinuation. Statistical analyses performed included one-way ANOVA, Welch's test and logistic regression.
Results: Out of 213 patients enrolled in JBCRG-16/Neo LaTH, we obtained dosage timing data from 143 (67%) patients: 16 (11%) after overnight fasting, 53 (37%) between meals, and 74 (52%) at bedtime. Serum lapatinib concentrations were obtained in 34/143 (24%) of patients. Dosage timing was not associated with ≥grade 2 diarrhea (8/16 (50%) after overnight fasting, 18/53 (34%) between meals, and 26/74 (35%) at bedtime; p = 0.48). However, multivariate analysis revealed that the after overnight fasting group is less likely to develop acne-like rash during La + T treatment regardless of age, BMI, or treatment.
Multivariate logistic regression analysis of factors predicting rash during La + T treatmentFactor Adjusted odds ratio95% confidence intervalp valueAge (years)≥55Reference <552.671.18-6.310.018*BMI (kg/m2)≥23Reference <231.040.45-2.390.933La + T duration6 weeksReference 12 weeks3.621.49-9.770.004*Concurrent endocrine treatmentYesReference No2.170.94-5.150.068Dosage timingAfter overnight fastingReference Others3.681.16-11.90.027*BMI cut off is based on Asian criteria for overweight status. La: Lapatinib, T: Trastuzumab, *statistically significant
In addition, serum lapatinib trough concentration and it's variability were significantly reduced in the after overnight fasting group (mean ± standard deviation (SD) = 0.35 ± 0.15 µg/ml, coefficient of variation (CV) = 42.7%) as compared to the others (mean ± SD = 0.77 ± 0.44 µg/ml, CV = 57.8%) (p<0.01) . The chance of pCR was not associated with dosage timing (8/16 (50%) after overnight fasting, 24/53, (45%) between meals, and 38/74 (51%) at bedtime; p = 0.79).
Conclusions: These data suggest that overnight fasting stabilizes the bioavailability of lapatinib, which may aid in managing lapatinib-induced rash without diminishing its therapeutic efficacy.
Citation Format: Tsuda M, Ishiguro H, Toriguchi N, Masuda N, Bando H, Ohgami M, Homma M, Morita S, Yamamoto N, Kuroi K, Takano T, Shimizu S, Toi M. Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-11-07.
Collapse
Affiliation(s)
- M Tsuda
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - H Ishiguro
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - N Toriguchi
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - N Masuda
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - H Bando
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - M Ohgami
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - M Homma
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - S Morita
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - N Yamamoto
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - K Kuroi
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - T Takano
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - S Shimizu
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| | - M Toi
- Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
| |
Collapse
|
50
|
Sukawa Y, Nosho K, Miura Y, Takano T, Ito M, Yonesaka K, Mori M, Tokunaga S, Kawada J, Okuda H, Sakamoto T, Hirashima Y, Uchino K, Miyata Y, Yoshimura K, Yamazaki K, Hironaka S, Boku N, Hyodo I, Muro K. Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|